ライフサイエンスコーパス: tetrahydrocannabinol

1 uracy was significantly reduced after Delta9-tetrahydrocannabinol.

2 or marijuana's bioactive ingredient Delta(9)-tetrahydrocannabinol.

3 inuation of chronic heavy use of cannabis or tetrahydrocannabinol.

4 abinoid receptor 1 stimulation with Delta(9)-tetrahydrocannabinol.

5 n the pharmacological properties of Delta(9)-tetrahydrocannabinol.

6 icated by the exogenous cannabinoid Delta(9)-tetrahydrocannabinol (1 microM) nor reversed by the sele

7 rocannabinol (THC-COOH), 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC), and 11-nor-9-carboxy-D

8 lead compound, (-)-3-(1-adamantyl)-Delta(8)-tetrahydrocannabinol (1a, AM411), was found to have robu

9 This system can be activated by Delta(9)-tetrahydrocannabinol, a major drug of abuse.

10 Delta9-Tetrahydrocannabinol administration enhanced activity fo

11 Furthermore, chronic Delta(9)-tetrahydrocannabinol administration, which reduces canna

12 n the nucleus accumbens after acute Delta(9)-tetrahydrocannabinol administration.

13 Delta9-Tetrahydrocannabinol also attenuated the normal time-dep

14 al structures of human CB1 in complex with a tetrahydrocannabinol (AM11542) and a hexahydrocannabinol

15 imols (maximum daily dose, 86.4 mg of Delta9-tetrahydrocannabinol and 80 mg of cannabidiol) or placeb

16 ecades, with particular emphasis on Delta(9)-tetrahydrocannabinol and cannabidiol.

17 Here we show that the cannabinoids Delta(9)-tetrahydrocannabinol and CP55940 decreased the power of

18 delta9-Tetrahydrocannabinol and endogenous cannabinoids (e.g.,

19 Trials assessing neuroprotection with tetrahydrocannabinol and lamotrigine are imminent; both

20 owever, therapeutic applications of Delta(9)-tetrahydrocannabinol and other CB1 orthosteric receptor

21 Both Delta(9)-tetrahydrocannabinol and the endogenous ligand, anandami

22 was also demonstrated with CP55940, Delta(9)-tetrahydrocannabinol, and cannabidiol, thus suggesting t

23 f abuse including cocaine, ethanol, Delta(9)-tetrahydrocannabinol, and opiates; the antipsychotic dru

24 hydroxypropyl)cyclohexan-1-ol) and Delta(9)-tetrahydrocannabinol are orthosteric agonists for the re

25 t HU210, a structural analog of (-)-Delta(9)-tetrahydrocannabinol, binds to brain cannabinoid (CB1) r

26 e nucleus accumbens after exposure to Delta9-tetrahydrocannabinol, but less is known about cannabis u

27 binol, delta-9-tetrahydrocannabinol, delta-8-tetrahydrocannabinol, cannabichromene, delta-9-tetrahydr

28 uana cigarette, a 2.5-mg dronabinol (delta-9-tetrahydrocannabinol) capsule, or a placebo capsule thre

29 0-CB1 receptor complex, and the (-)-Delta(9)-tetrahydrocannabinol-CB1 receptor complex, we found that

30 with users' urinary 11-nor-9-carboxy-Delta9-tetrahydrocannabinol concentrations at study entry.

31 ith high affinity and specificity for delta9-tetrahydrocannabinol could be valuable immunopharmacothe

32 ion phase from 5 mg to a maximum of 25 mg of tetrahydrocannabinol daily and a 10 week maintenance pha

33 to the determination of cannabidiol, delta 8-tetrahydrocannabinol (delta 8-THC), delta 9-tetrahydroca

34 delta 9-Tetrahydrocannabinol (delta 9-THC) a prototypic compound

35 -tetrahydrocannabinol (delta 8-THC), delta 9-tetrahydrocannabinol (delta 9-THC), and cannabinol in pu

36 (QSAR) for the side-chain region of Delta(8)-tetrahydrocannabinol (Delta(8)-THC) analogues is reporte

37 nalogue of the phytocannabinoid (-)-Delta(8)-tetrahydrocannabinol (Delta(8)-THC), was shown to have i

38 55,212 (64%), anandamide (42%), and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) (44%) all initiated

39 f antisense oligodeoxynucleotide to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other naturally

40 The memory-disruptive effects of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and the synthetic ca

41 ents following repeated exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) are associated with

42 nd 2 (CB1 and CB2) agonists such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC) can produce toleranc

43 Delta(9)-tetrahydrocannabinol (Delta(9)-THC) is an effective anti

44 d the acute, dose-related effects of delta-9-tetrahydrocannabinol (Delta(9)-THC) on psychophysiologic

45 The acute, dose-related effects of Delta-9-tetrahydrocannabinol (Delta(9)-THC) on the auditory stea

46 -occurring Cannabis sativa alkaloid Delta(9)-tetrahydrocannabinol (Delta(9)-THC) or the synthetic can

47 reported that intracerebellar (ICB) Delta(9)-tetrahydrocannabinol (Delta(9)-THC) produces dose-depend

48 etween its psychoactive constituent, Delta-9-tetrahydrocannabinol (Delta(9)-THC), and CB(1) receptors

49 re sensitive to acutely administered delta-9-tetrahydrocannabinol (Delta(9)-THC), have delayed tolera

50 ychoactive ingredient of marijuana, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), increased GluR2-lac

51 constituent of Cannabis sativa L., Delta(9)-tetrahydrocannabinol (Delta(9)-THC), led to the identifi

52 he naturally occurring cannabinoid, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), releases dynorphin

53 Delta-9-tetrahydrocannabinol (Delta(9)-THC), the main psychoacti

54 widely used recreational agent, and Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the major active co

55 In contrast, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the major psychoact

56 ed in the psychotomimetic effects of delta-9-tetrahydrocannabinol (Delta(9)-THC), the principal activ

57 t of marijuana, the partial agonist Delta(9)-tetrahydrocannabinol (Delta(9)-THC).

58 In contrast to marijuana, where Delta(9)-tetrahydrocannabinol (Delta(9)THC) is metabolized to onl

59 al activation under the influence of delta-9-tetrahydrocannabinol (delta-9-THC) and cannabidiol (CBD)

60 arijuana and its active constituent, delta-9-tetrahydrocannabinol (delta-9-THC), may reduce pain sens

61 investigated whether the effects of delta-9-tetrahydrocannabinol (delta-9-THC), the main psychoactiv

62 nnabigerol, cannabidiol, cannabinol, delta-9-tetrahydrocannabinol, delta-8-tetrahydrocannabinol, cann

63 Chronic Delta9-tetrahydrocannabinol (Delta9-THC) administration produce

64 Delta9-Tetrahydrocannabinol (delta9-THC) fails to inhibit EPSCs

65 eatment of SIV-infected macaques with Delta9-tetrahydrocannabinol (Delta9-THC) increased survival and

66 d macaques, chronic administration of Delta9-tetrahydrocannabinol (Delta9-THC) inhibited viral replic

67 Delta9-tetrahydrocannabinol (delta9-THC) is an effective anti-e

68 Delta9-tetrahydrocannabinol (Delta9-THC) is the principal psych

69 e concomitant increase in potency of delta-9-tetrahydrocannabinol (Delta9-THC) may have contributed t

70 o examine the effects of estrogen and delta9-tetrahydrocannabinol (delta9-THC) on learning and memory

71 were treated with escalating doses of Delta9-tetrahydrocannabinol (Delta9-THC) or R+-[2,3-dihydro-5-m

72 psychoactive ingredient in cannabis, Delta9-tetrahydrocannabinol (Delta9-THC), affects the brain mai

73 psychoactive component of marijuana, Delta9-tetrahydrocannabinol (Delta9-THC), are presented.

74 central hypothesis that exposure to Delta-9-tetrahydrocannabinol (Delta9-THC), the major psychoactiv

75 Delta9-Tetrahydrocannabinol (Delta9-THC), the major psychoactiv

76 improvement in affinity for (-)-trans-delta9-tetrahydrocannabinol (delta9-THC).

77 main active chemical in marijuana is delta9-tetrahydrocannabinol (delta9-THC); hence, monoclonal ant

78 s with oral cannabis extract (n=211), Delta9-tetrahydrocannabinol (Delta9-THC; n=206), or placebo (n=

79 (-)-Delta9-Tetrahydrocannabinol ((-)-Delta9-THC) is the major activ

80 Bath applied Delta(9)-tetrahydrocannabinol depressed GABA cell activity, there

81 c syntheses of four photoswitchable Delta(9)-tetrahydrocannabinol derivatives (azo-THCs) from a centr

82 he CB(1) receptor agonist (-)-11-OH-Delta(9)-tetrahydrocannabinol dimethylheptyl.

83 (EC(50) = 3.7 microM), followed by Delta(9)-tetrahydrocannabinol (EC(50) = 14 microM) and cannabinol

84 Delta9-Tetrahydrocannabinol enhanced WM activity network-wide f

85 ptors, such as the phytocannabinoid Delta(9)-tetrahydrocannabinol, exert a remarkable array of therap

86 The CB(1) receptor agonist Delta(9)-tetrahydrocannabinol exerted a biphasic control of fear

87 active compound in herbal cannabis, Delta(9)-tetrahydrocannabinol, exerts all of its known central ef

88 ors, including CP55940, HU-210, and Delta(9)-tetrahydrocannabinol, failed to stimulate [(35)S]GTP gam

89 l (11-OH-THC), and 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol glucuronide (THC-COO-glu).

90 ychoactive ingredient in marijuana, Delta(9)-tetrahydrocannabinol, has been shown to inhibit adenylyl

91 Although cannabinoids, such as Delta(9)-tetrahydrocannabinol, have been studied extensively for

92 pal bioactive component of marijuana, delta9-tetrahydrocannabinol, have been used for thousands of ye

93 of cannabinoid agonists, including Delta(9)-tetrahydrocannabinol, HU-210, CP55,940, 2-arachidonoylgl

94 6) and (-)-11-hydroxydimethylheptyl-Delta(8)-tetrahydrocannabinol (HU210) were drastically reduced (5

95 pic and appetite-inducing component Delta(9)-tetrahydrocannabinol, i.e., the endocannabinoid 2-arachi

96 hanism for the addictive effects of Delta(9)-tetrahydrocannabinol in juvenile-adolescents, by potenti

97 Delta9-Tetrahydrocannabinol increased psychotic symptoms and le

98 a novelly identified TRPV2 agonist, Delta(9)-tetrahydrocannabinol, indicating that human TRPV2 is fun

99 c agonist 1,1-dimethylbutyl-1-deoxy-Delta(9)-tetrahydrocannabinol (JWH133).

100 tally induced higher cannabinoid [(-)-Delta9-tetrahydrocannabinol] levels constrain preimplantation e

101 rticipants were randomly assigned to a 3.95%-tetrahydrocannabinol marijuana cigarette, a 2.5-mg drona

102 ceptor agonism using R(+)-WIN 55,212, delta9-tetrahydrocannabinol, methanandamide and JWH-133 quantit

103 vestigated whether oral dronabinol (Delta(9)-tetrahydrocannabinol) might slow the course of progressi

104 logs of the cyclic ether O,2-propano-delta 8-tetrahydrocannabinol (O,2-propano-delta 8-THC) point to

105 But the variable effects of Delta(9)-tetrahydrocannabinol obscure the interpretation of these

106 Chronic injections of Delta(9)-tetrahydrocannabinol occluded LTD compared with vehicle

107 the brain's reward circuit, and how Delta(9)-tetrahydrocannabinol occludes this plasticity.

108 estigating effects of the eCB agonist Delta9-tetrahydrocannabinol on WM function in 17 healthy volunt

109 Exogenous cannabinoids, such as tetrahydrocannabinol, produce their biological effects t

110 ychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol, produces in humans subjective resp

111 ctive constituent of marijuana, (-)-Delta(9)-tetrahydrocannabinol, produces most of its physiological

112 Yet, contrary to Delta(9)-tetrahydrocannabinol, SCs may lead to severe health cons

113 cannabinoid agonists WIN 55,212-2 and delta9-tetrahydrocannabinol shortened the modal response time,

114 ated cumulative lifetime exposure of Delta-9-tetrahydrocannabinol (THC) (mean 168 +/- 45 versus 244 +

115 oses (30-240 mug/kg) of intravenous Delta(9)-tetrahydrocannabinol (THC) administration on the perform

116 ch indicates that administration of Delta(9)-tetrahydrocannabinol (THC) alters threat perception and

117 xy-substituted hexahydrocannabinol (HHC) and tetrahydrocannabinol (THC) analogues in which a seven at

118 an increase of the psychoactive compound (9)-tetrahydrocannabinol (THC) and a decrease of the potenti

119 The plant-derived cannabinoids delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both ha

120 Delta(9)-Tetrahydrocannabinol (THC) and cannabidiol (CBD) occur n

121 s isolated from cannabis, including Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD).

122 icinal applications of pure forms of delta-9-tetrahydrocannabinol (THC) and crude marijuana are being

123 only abused psychotropic compounds, Delta(9)-tetrahydrocannabinol (THC) and heroin, on adult zebrafis

124 The involvement of dynorphin on Delta-9-tetrahydrocannabinol (THC) and morphine responses has be

125 Delta(9)-Tetrahydrocannabinol (THC) and other cannabinoids are re

126 antagonist, blocks acute effects of Delta-9-tetrahydrocannabinol (THC) and other CB1 cannabinoid ago

127 ne, methadone, cocaine, heroin, codeine, and tetrahydrocannabinol (THC) and their major human metabol

128 Anandamide (AEA) and delta9-tetrahydrocannabinol (THC) are endogenous and exogenous

129 Placental transfer of Delta9-tetrahydrocannabinol (THC) during pregnancy has the pote

130 Natural cannabinoids such as Delta(9)-tetrahydrocannabinol (THC) effectively modulate immune c

131 csh) of adults following adolescent Delta(9)-tetrahydrocannabinol (THC) exposure.

132 tamine (MDEA), morphine, cocaine, and Delta9-tetrahydrocannabinol (THC) from a single blood spot.

133 Cannabidiol (CBD) and (9)-tetrahydrocannabinol (THC) have well documented immunomo

134 to investigate whether exposure to Delta(9)-tetrahydrocannabinol (THC) in adolescent rats might enha

135 murine tumors EL-4, LSA, and P815 to delta-9-tetrahydrocannabinol (THC) in vitro led to a significant

136 Chronic exposure to Delta9-tetrahydrocannabinol (THC) induces tolerance to cannabin

137 maging (MRI) to study the effects of delta-9-tetrahydrocannabinol (THC) infusion on brain blood flow

138 ies to attenuate certain aspects of Delta(9)-tetrahydrocannabinol (THC) intoxication.

139 Delta(9)-Tetrahydrocannabinol (THC) is the primary cannabinoid of

140 Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive c

141 Currently, Delta(9)-tetrahydrocannabinol (THC) is used as the primary target

142 Like tetrahydrocannabinol (THC) itself, many synthetic cannab

143 positively with creatinine-normalized Delta9-tetrahydrocannabinol (THC) levels.

144 emic acid (AJA) is a synthetic analog of the tetrahydrocannabinol (THC) metabolite THC-11-oic acid; T

145 ffects of the endocannabinoid agonist Delta9-tetrahydrocannabinol (THC) on executive function in 20 h

146 m mediate the inhibitory effects of Delta(9)-tetrahydrocannabinol (THC) on motor coordination.

147 d the effects of repeated exposure to Delta9-tetrahydrocannabinol (THC) on performance of spatial and

148 self-administration of cannabinoids delta-9-tetrahydrocannabinol (THC) or anandamide in squirrel mon

149 f cannabinoid CB1 receptors (CB1R) by delta9-tetrahydrocannabinol (THC) produces a variety of negativ

150 Treatment with Delta(9)-Tetrahydrocannabinol (THC) resulted in the activation of

151 Exogenous cannabinoids such as tetrahydrocannabinol (THC) stimulate appetite and food i

152 y consumed plant (phyto)cannabinoid Delta(9)-tetrahydrocannabinol (THC)(1).

153 cannabinoids (cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (THC)) on arrestin2-, Galpha(i/o)-,

154 bited potentiation produced by both Delta(9)-tetrahydrocannabinol (THC), a major psychoactive compone

155 Addition of Delta(9)-tetrahydrocannabinol (THC), a major psychoactive compone

156 ull agonist at CB(1) receptors, and Delta(9)-tetrahydrocannabinol (THC), a partial agonist, on the su

157 udy this phenomenon, we assessed how delta-9-tetrahydrocannabinol (THC), a primary psychoactive ingre

158 1 (CB1) is the principal target of Delta(9)-tetrahydrocannabinol (THC), a psychoactive chemical from

159 e psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), activated cerebellar microgl

160 t binds the active constituent of marijuana, tetrahydrocannabinol (THC), and a postulated endogenous

161 psychoactive compound in marijuana, Delta(9)-tetrahydrocannabinol (THC), and its metabolites are emer

162 ell as exogenous cannabinoids such as Delta9-tetrahydrocannabinol (THC), are mediated by two subtypes

163 (2-AG), anandamide (AEA), CP55,940, Delta(9)-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC+C

164 (UHPLC-MS/MS) for analysis of urinary Delta9-tetrahydrocannabinol (THC), cannabidiol and cannabinol,

165 ry actions of the phytocannabinoids Delta(9)-tetrahydrocannabinol (THC), cannabidiol, cannabichromene

166 tting both detection and mapping of Delta(9)-tetrahydrocannabinol (THC), cannabinol (CBN), cannabidio

167 Unlike Delta(9)-tetrahydrocannabinol (THC), CBD does not act through the

168 sychotropic component in marijuana, Delta(9)-tetrahydrocannabinol (THC), has also been shown to media

169 ow 10(-7) Torr, such as tetryl, cocaine, and tetrahydrocannabinol (THC), have been successfully detec

170 sychoactive component of marijuana, Delta(9)-tetrahydrocannabinol (THC), is a signaling network that

171 (alpha7nAChRs) modulate effects of Delta(9)-tetrahydrocannabinol (THC), marijuana's main psychoactiv

172 the active ingredient of cannabis, Delta(9)-tetrahydrocannabinol (THC), on sexual behavior in female

173 chronic exposure to vehicle solution, Delta9-tetrahydrocannabinol (THC), or the cannabinoid agonist R

174 nabinoids cannabichromene (CBC) and Delta(1)-tetrahydrocannabinol (THC), respectively] is predicted i

175 The marijuana cannabinoid, delta 9-tetrahydrocannabinol (THC), suppresses immunity to Legio

176 (9) -Tetrahydrocannabinol (THC), the active constituent of Ca

177 ent doses and treatment regimens of Delta(9)-tetrahydrocannabinol (THC), the main active ingredient i

178 strated that adolescent exposure to Delta(9)-tetrahydrocannabinol (THC), the main psychoactive compon

179 we show that adolescent exposure to Delta(9)-tetrahydrocannabinol (THC), the main psychoactive compon

180 avioral effects similar to those of Delta(9)-tetrahydrocannabinol (THC), the main psychoactive ingred

181 The effects of Delta(9)-tetrahydrocannabinol (THC), the main psychoactive ingred

182 ctive component of tobacco, and (-)-Delta(9)-tetrahydrocannabinol (THC), the main psychoactive ingred

183 Delta(9)-Tetrahydrocannabinol (THC), the major bioactive componen

184 In this study, we show that Delta-9-tetrahydrocannabinol (THC), the major psychoactive compo

185 Here we report that Delta9-tetrahydrocannabinol (THC), the major psychoactive compo

186 binoid receptor, the main target of Delta(9)-tetrahydrocannabinol (THC), the most prominent psychoact

187 Reinforcing effects of Delta(9)-tetrahydrocannabinol (THC), the primary active ingredien

188 er the influence of exogenously administered tetrahydrocannabinol (THC), the primary CB found in mari

189 The anxiolytic effects of delta(9)-tetrahydrocannabinol (THC), the primary psychoactive ing

190 Delta9-tetrahydrocannabinol (THC), the principal bioactive comp

191 Delta(9)-tetrahydrocannabinol (THC), the principal psychoactive i

192 (1)Rs) mediate the effects of triangle up(9)-tetrahydrocannabinol (THC), the psychoactive component i

193 Delta(9)-tetrahydrocannabinol (THC), the psychoactive component o

194 ngredient in chilli peppers, and by Delta(9)-tetrahydrocannabinol (THC), the psychoactive component o

195 behavior by laboratory animals with delta-9-tetrahydrocannabinol (THC), the psychoactive ingredient

196 tions of its main active ingredient, delta-9-tetrahydrocannabinol (THC), to be more harmful (in terms

197 ychoactive constituent in cannabis, Delta(9)-tetrahydrocannabinol (THC), was isolated in the mid-1960

198 Delta9-Tetrahydrocannabinol (THC), which is the main bioactive

199 ne, methadone, cocaine, heroin, codeine, and tetrahydrocannabinol (THC).

200 , and the psychotropic cannabinoid (-)Delta9-tetrahydrocannabinol (THC).

201 is, specifically the psychoactive substance, tetrahydrocannabinol (THC).

202 296 in hGlyR-alpha1 potentiation by Delta(9)-tetrahydrocannabinol (THC).

203 oylecgonine (BE) and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol (THC-COOH) were shown to be strongl

204 metabolite of THC, 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THC-COOH) with chlorine.

205 nd the metabolites 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THC-COOH), 11-hydroxy-Delta(9)-tet

206 The cannabinoid receptor agonist, Delta(9)-tetrahydrocannabinol (THC; dronabinol), decreases mariju

207 ed marijuana to orally administered Delta(9)-tetrahydrocannabinol (THC; dronabinol).

208 are mimicked by administration of (-)-Delta9-tetrahydrocannabinol (THC; the major psychoactive consti

209 Marijuana (hereafter "tetrahydrocannabinol [THC]") use has been associated wit

210 ecgonine (BE), and 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in this matrix.

211 endogenous cannabinoids, as well as Delta(9)-tetrahydrocannabinol, the main plant psychoactive consti

212 ns after the acute administration of delta-9-tetrahydrocannabinol, the primary psychoactive constitue

213 receptors also mediate the effects of Delta9-tetrahydrocannabinol, the primary psychoactive ingredien

214 rs CB(1) and CB(2) are activated by Delta(9)-tetrahydrocannabinol, the psychoactive ingredient of can

215 to mitigate the central effects of Delta(9)-tetrahydrocannabinol through the CB1 receptor.

216 sulting in a change in the ratio of Delta(9)-tetrahydrocannabinol to cannabidiol from 14 times in 199

217 abinoids such as the marijuana component (9)-tetrahydrocannabinol, to heterotrimeric G12/G13 proteins

218 everal weeks after the cessation of Delta(9)-tetrahydrocannabinol treatment.

219 ore study; positive 11-nor-9-carboxy-delta-9-tetrahydrocannabinol urine levels) and cannabis naive co

220 ore study; positive 11-nor-9-carboxy-delta-9-tetrahydrocannabinol urine levels) and cannabis-naive co

221 tic remodeling that can occur after Delta(9)-tetrahydrocannabinol use.

222 e range of 0.05-60 mg/kg, and the content of tetrahydrocannabinol varied between 3.23 and 69.5 mg/kg.

223 in the nucleus accumbens induced by Delta(9)-tetrahydrocannabinol was blocked in mice lacking the Hcr

224 We additionally found that Delta9-tetrahydrocannabinol, which has been shown to attenuate